Compare · IDXX vs QCLS
IDXX vs QCLS
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Q/C Technologies Inc. (QCLS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and QCLS operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $43.11B, about 9441.3x QCLS ($4.6M).
- Over the past year, IDXX is down 13.0% and QCLS is down 88.0% - IDXX leads by 75.0 points.
- IDXX has been more active in the news (4 items in the past 4 weeks vs 3 for QCLS).
- IDXX has more recent analyst coverage (25 ratings vs 0 for QCLS).
- Company
- IDEXX Laboratories Inc.
- Q/C Technologies Inc.
- Price
- $560.52+2.44%
- $0.54-6.74%
- Market cap
- $43.11B
- $4.6M
- 1M return
- +10.63%
- -30.51%
- 1Y return
- -13.04%
- -88.04%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- 2014
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 0
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Latest IDXX
- Goldman initiated coverage on IDEXX Labs with a new price target
- KeyBanc Capital Markets initiated coverage on IDEXX Labs
- IDEXX Laboratories to Release 2026 Third Quarter Financial Results
- Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
- IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
- IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
- Director Kingsley Lawrence D exercised 2,203 shares at a strike of $114.17 and sold $1,172,178 worth of shares (2,203 units at $532.08) (SEC Form 4)
- IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- EVP, CFO and Treasurer Emerson Andrew exercised 265 shares at a strike of $178.26 and covered exercise/tax liability with 86 shares, increasing direct ownership by 4% to 4,421 units (SEC Form 4)
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
Latest QCLS
- Executive Chairman Silverman Joshua was granted 94,010 shares, increasing direct ownership by 80% to 210,845 units (SEC Form 4)
- Amendment: Executive Chairman Silverman Joshua was granted 16,806 shares, increasing direct ownership by 17% to 116,835 units (SEC Form 4)
- Q/C Technologies Announces Research Collaboration with Sandia National Laboratories, a $5 Billion U.S. Department of Energy Lab
- SEC Form 3 filed by new insider Ehrlichman Yossef
- Q/C Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Q/C Technologies Names Yossef Ehrlichman Chief Technology Officer to Lead Optical Processor Development
- Q/C Technologies Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
- SEC Form 3 filed by new insider Fagan Charles Todd
- SEC Form 10-Q filed by Q/C Technologies Inc.
- Q/C Technologies Appoints Veteran Silicon Photonics Engineer Yossef Ehrlichman as Founding Manager, Photonic Integrated Circuit (PIC) Development